GLP-1 vs sglt2
You are deciding between two options.
Reference and calculator, not medical advice. Dosing figures below are transcribed from FDA-approved prescribing information and link back to it. Last reviewed August 2026.
These two classes are compared constantly in diabetes care and almost never belong in the same conversation about weight, because weight reduction is not among the labelled indications for SGLT2 inhibitors at all.
What SGLT2 inhibitors actually is
A class that makes the kidney excrete glucose in urine. Empagliflozin (Jardiance) and dapagliflozin (Farxiga) are the common ones.
- FDA-approved medication
- Yes
- Approved for
- Cardiovascular death and heart-failure hospitalisation, chronic kidney disease progression, and type 2 diabetes. Weight reduction is not among the labelled indications.
- Difference that matters
- Not a weight-loss medication at all. Any weight change is a side effect rather than the point, which is why the comparison rarely makes sense as posed.
This page describes what each thing is and what it is approved for. It does not compare how well they work, because that is a question for a prescriber with your history in front of them.
Read the Jardiance indications and the framing becomes clear: reducing cardiovascular death and heart-failure hospitalisation, slowing chronic kidney disease progression, and reducing cardiovascular death in type 2 diabetes. It is a cardiorenal and glycaemic drug. Any weight change is a side effect of excreting glucose, not the purpose.
Side-by-side
Structural facts from each product’s prescribing information.
| Product | Active ingredient | Indication | Frequency | Start | Max labelled | Steps to max |
|---|---|---|---|---|---|---|
| Ozempic Novo Nordisk | Semaglutide | Type 2 diabetes | Weekly | 0.25 mg | 2 mg | 4 |
| Mounjaro Eli Lilly | Tirzepatide | Type 2 diabetes | Weekly | 2.5 mg | 15 mg | 6 |
| Rybelsus Novo Nordisk | Semaglutide (oral) | Type 2 diabetes | Daily | 3 mg | 14 mg | 3 |
Where the comparison does make sense is type 2 diabetes, where both classes are used and both carry cardiovascular and kidney outcome data. Which fits a particular person depends on their kidney function, cardiac history and glycaemic targets — a specialist decision that no comparison table substitutes for.
Common questions
- Can they be taken together?
- Combining classes is common in type 2 diabetes management and entirely a prescriber decision. Nothing on this site should be read as guidance on it.
- Do SGLT2 inhibitors cause weight loss?
- Weight change is described in their labelling as an effect, not an indication. They are not prescribed for weight management and are not approved for it.
Sources and last review
Every dosing figure on this page is transcribed from an FDA-approved label and links back to it. Conversions are arithmetic you can repeat by hand. Nothing here is reviewed by a clinician, and this site does not employ one — which is exactly why what I do publish stays traceable to its source.
- Ozempic (Semaglutide) prescribing information — Novo Nordisk, label revised 10 June 2026, checked 7 August 2026
- Mounjaro (Tirzepatide) prescribing information — Eli Lilly, label revised 6 May 2026, checked 7 August 2026
- Rybelsus (Semaglutide) prescribing information — Novo Nordisk, label revised 20 May 2026, checked 7 August 2026
Transcribed from the labels above and checked by me — Gavin, who builds this site, takes a GLP-1, and is not a clinician. Last reviewed August 2026. Found an error? [email protected] — I treat corrections as bugs. How this site is built and funded.
Also searched as: glp-1 vs sglt2